Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients With Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 24 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

21 Oct 2025 Long-term efficacy and safety data presented in the SpringWorks Therapeutics.
21 Oct 2025 According to a SpringWorks Therapeutics, the long-term follow-up data from DeFi trial were presented at the 2024 Connective Tissue Oncology Society Meeting.
21 Oct 2025 According to a SpringWorks Therapeutics, company announced the publishing of long-term efficacy and safety data from the Phase 3 DeFi trial in the Journal of Clinical Oncology (JCO).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com